

Evaluation of Efficacy and Safety of Alcarisa (Hyaluronic Acid Produced by Espad Pharmed Co.) for Restoration of Mid-face Volume

NCT07126912

Status	RECRUITING
Phase	Not Applicable
Sponsor	Espad Pharmed
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (4)

- Men and women aged 30 to 65 years
- Individuals with moderate to significant mid-face volume loss (score 3 to 4) based on changes in MFVDS (in cases of asymmetry between the two sides of the face, the more severe side will be considered)
- Ability to comply with visit schedules and study procedures
- Signed the informed consent form and agreed to 6-month follow-up

Exclusion (14)

- History of Type I hypersensitivity reactions or anaphylaxis
- Known allergy or sensitivity to any components of the filler, lidocaine, or to proteins from the HA-producing microorganisms (Streptococci)
- History of hypertrophic or keloid scarring, or bleeding disorders in the injection area
- Active inflammatory processes, infections, lesions (malignant or benign), or scars in the injection area
- History of streptococcal diseases (such as recurrent sore throat or acute rheumatic fever) in the past 6 months
- ... and 9 more (see full listing online)

Locations (2 total)

Center for Research and Training in Skin Disease and Leprosy, Tehran, Tehran Province, Iran
Orchid Pharmed, Medical Department, Tehran, Tehran Province, Iran